Semaglutide and Lifestyle Counseling for Adolescent Obesity Management Trial

The prevalence of severe obesity among adolescents in the United States has reached an unprecedented high, presenting a significant challenge for healthcare systems due to its refractory nature. Current clinical guidelines primarily recommend intensive behavioral interventions for all ages and classes of obesity, with studies showing that ≥26 contact hours over 2-12 months lead to weight loss, and ≥52 contact hours result in even greater weight loss and improved cardiometabolic risk factors. This ongoing clinical trial aims to address the knowledge gap by evaluating if combining intensive behavioral therapy with a GLP-1 agonist like semaglutide can provide a more effective, safe, and durable treatment for adolescent obesity.

As an active trial that is currently not recruiting, specific results are not yet available. However, based on the study's rationale, the researchers anticipate that the combined semaglutide and behavioral therapy intervention will lead to significantly greater weight loss and improvements in cardiometabolic risk factors compared to behavioral therapy alone. The study aims to demonstrate that pharmacotherapy can enhance the effects of lifestyle changes, potentially achieving weight loss outcomes superior to those seen with behavioral interventions providing even ≥52 contact hours. The primary hypothesis is that the Semaglutide and Behavioral Program will yield a statistically significant and clinically meaningful reduction in body weight and BMI in adolescents with obesity.